Allogeneic tumor cell vaccines: the promise and limitations in clinical trials
about
Concerning immune synapses: a spatiotemporal timelineThe Dichotomy of Tumor Exosomes (TEX) in Cancer Immunity: Is It All in the ConTEXt?Immunization with recombinantly expressed glycan antigens from Schistosoma mansoni induces glycan-specific antibodies against the parasite.Induction and characterization of anti-tumor endothelium immunity elicited by ValloVax therapeutic cancer vaccine.Current status of autologous breast tumor cell-based vaccines.Development of Membrane-Bound GM-CSF and IL-18 as an Effective Tumor Vaccine.Encapsulated cellular implants for recombinant protein delivery and therapeutic modulation of the immune system.Autologous tumor lysate/Bacillus Calmette-Guérin immunotherapy as an adjuvant to conventional breast cancer therapyInfluenza virus-like particles engineered by protein transfer with tumor-associated antigens induces protective antitumor immunity.Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12.Belagenpumatucel-L for the treatment of non-small cell lung cancer.Immune effect and safety evaluation of vaccine prepared by dendritic cells modified by rAAV-carrying BCSG1 gene.Vesigenurtacel-L (HS-410) in the management of high-grade nonmuscle invasive bladder cancer.Novel agents for the treatment of childhood leukemia: an update.Vaccine and immune cell therapy in non-small cell lung cancer.SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4+ T Lymphocytes.
P2860
Q26752454-63749697-8833-47C6-B45B-60CD114C8498Q26773307-F5E1F96C-51DD-4BE2-B368-751A7056B4C0Q33684607-1FE5E311-C5C4-43DC-90FA-14CAC75B3409Q33709802-4234F3A7-0144-43C0-B759-866F60E791C6Q35154214-3D527A55-243B-4DD5-B992-678DA15C63B5Q35695115-E6F307D0-D991-4FB6-ABE1-B553A1E45DBEQ35723422-F6EF6728-370A-49A9-AF9C-25B8B768BE4DQ36171703-3F9EA534-5A08-4440-B1FD-79148FC6A324Q36207818-4D59A88C-B4A2-4A08-9632-864D08D4D7B7Q37309250-3F891BF1-79F7-4F60-906D-F65EDD2A4A5AQ38554476-D49E3208-89F3-4588-AE0F-F3C8B7D55B97Q38750395-D53AD062-D38E-4D0A-993C-422152CCD4BFQ38823147-A099A07D-B5E0-48FF-8CBA-5ADACE4CB800Q39455649-29A3E937-EA8B-4B4B-8F35-4E9A834C004AQ55284807-E4FEDDA4-7196-44F7-B7FA-CBBC6C2460A6Q55342016-78A520FB-EF7C-40C9-A5A5-8CAEDBE961EA
P2860
Allogeneic tumor cell vaccines: the promise and limitations in clinical trials
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Allogeneic tumor cell vaccines: the promise and limitations in clinical trials
@ast
Allogeneic tumor cell vaccines: the promise and limitations in clinical trials
@en
Allogeneic tumor cell vaccines: the promise and limitations in clinical trials
@nl
type
label
Allogeneic tumor cell vaccines: the promise and limitations in clinical trials
@ast
Allogeneic tumor cell vaccines: the promise and limitations in clinical trials
@en
Allogeneic tumor cell vaccines: the promise and limitations in clinical trials
@nl
prefLabel
Allogeneic tumor cell vaccines: the promise and limitations in clinical trials
@ast
Allogeneic tumor cell vaccines: the promise and limitations in clinical trials
@en
Allogeneic tumor cell vaccines: the promise and limitations in clinical trials
@nl
P2093
P2860
P3181
P356
P1476
Allogeneic tumor cell vaccines: the promise and limitations in clinical trials
@en
P2093
Danielle Daniels
Erica N Bozeman
Imade E Imasuen
Periasamy Selvaraj
Sanjay Srivatsan
P2860
P3181
P356
10.4161/HV.26568
P407
P577
2014-01-01T00:00:00Z